Could a protein on blood cancer cells lead to a new treatment?

NCT ID NCT07455500

Not yet recruiting Knowledge-focused Sponsor: University Hospital, Grenoble Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at a protein called IL-1RAP found on the surface of certain blood cancer cells in myelodysplastic syndromes (MDS). Researchers want to see if this protein can be targeted by a special immune therapy called CAR-T cells. They will collect bone marrow and blood samples from 120 people with MDS to study the protein and test the therapy in the lab and in mice. This is a first step toward possibly developing a new treatment for high-risk MDS.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IL-1RAP-targeted CAR-T cells (investigational immunotherapy)
What this could lead to: If successful, this could point toward a new immunotherapy treatment for high-risk myelodysplastic syndromes, a condition with few options beyond stem cell transplant.
What could go wrong: This is a very early, lab-based study using patient samples and mice. It does not test the therapy in humans yet, so it may not work in actual patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELODYSPLASTIC SYNDROME

More trials for these conditions

Other studies related to the condition(s) this trial covers.